Totus Medicines
A Californiain biotech developing small molecule medicines using a novel DNA-encoded covalent library technology combined with AI.
The company's novel platform can find drugs that are dramatically superior to molecules discovered through previous technologies, including drug candidates for currently undruggable targets.
In December 2023, Totus closed a $66M Series B financing led by DCVC Bio.
Latest Totus Medicines News & Features
16 December 2023
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze